Tvardi Therapeutics, Inc. (TVRD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.70M
Last updated: Nov 17, 2026 at 4:10 PM ET
Tvardi Therapeutics, Inc. (TVRD) Stock Chart
Tvardi Therapeutics (TVRD) has a latest price of $1.01 on Nov 17, 2026, 82.2% below its 52-week high of $5.69. Its price fell 74.9% over the past 12 months. The month-end price fell 99.7% over the 10 years through Oct 2026, a compound annual decline of 43.8%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $935.75 in Nov 2019 and its lowest $0.79 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart TVRD with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for TVRD.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 46.3%, and over 6 months it fell 72.8%. The month-end price fell 98.3% over the 3 years through Oct 2026, a compound annual decline of 74.3%.
| Period | Change |
|---|---|
| 1 month | +4.1% |
| 3 months | -46.3% |
| 6 months | -72.8% |
| 12 months | -74.9% |
| 12 months, with dividends | -74.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -98.3% | -74.3% |
| 5 years | -99.9% | -73.5% |
| 10 years | -99.7% | -43.8% |
Price by Year
Its best calendar year was 2017, when the price rose 31.8%, and its weakest was 2023, when it fell 93.1%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $0.79 | -81.6% |
| 2025 | $4.30 | -76.6% |
| 2024 | $18.36 | -31.4% |
| 2023 | $26.76 | -93.1% |
| 2022 | $386.83 | -11.8% |
| 2021 | $438.70 | -19.5% |
| 2020 | $544.95 | -6.1% |
| 2019 | $580.25 | +23.9% |
| 2018 | $468.23 | +6.2% |
| 2017 | $440.86 | +31.8% |
Trading Range
The price is 15.7% below its 50-day average of $1.20 and 60.6% below its 200-day average of $2.56.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.01 | |
| 52-week high | $5.69 | -82.2% |
| 52-week low | $0.77 | +30.7% |
| 50-day average | $1.20 | -15.7% |
| 200-day average | $2.56 | -60.6% |
Price Risk
Over 3 years, its largest fall from a peak was 98.2%.
| Measure | Value |
|---|---|
| 1-year beta | 1.81 |
| Largest fall, 1 year | -84.1% |
| Largest fall, 3 years | -98.2% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About TVRD
What is TVRD's 1-year price change?
Tvardi Therapeutics's price fell 74.9% over the past 12 months. With dividends included, the 12-month total return was -74.9%.
What is TVRD's 5-year price change?
Tvardi Therapeutics's month-end price fell 99.9% over the 5 years through Oct 2026, a compound annual decline of 73.5%. These figures leave out dividends.
What is TVRD's 52-week high and low?
Tvardi Therapeutics's 52-week high is $5.69 and its 52-week low is $0.77. Its latest price of $1.01 on Nov 17, 2026 is 82.2% below the high.
What is TVRD's beta?
Tvardi Therapeutics's 1-year beta against the S&P 500 is 1.81, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 84.1%.
Is the TVRD chart free?
Yes. Advanced Charting for TVRD is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
TVRD pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors